Literature DB >> 15655831

Effect of mutated IkappaBalpha transfection on multidrug resistance in hilar cholangiocarcinoma cell lines.

Ru-Fu Chen1, Zhi-Hua Li, Xian-He Kong, Ji-Sheng Chen.   

Abstract

AIM: To explore the expression effect of mutated IkappaBalpha transfection on multidrug resistance gene (MDR-1) in hilar cholangiocarcinoma cells by inhibiting the activity of nuclear transcription factor-kappaB (NF-kappaB).
METHODS: We used the mutated IkappaBalpha plasmid to transfect QBC(939)HCVC+ cells and QBC939 cells, and electrophoretic gel mobility shift assay (EMSA) to detect the binding activity of NF-kappaB DNA and the effect of the transfecting mutated IkappaBalpha plasmid on multidrug resistance gene (MDR-1) in hilar cholangiocarcinoma cells and its expression protein (P-GP).
RESULTS: Plasmid DNA was digested by restriction enzymes Xbal and Hand III, and its product after electrophoresis showed two bands with a big difference in molecular weight, with a size of 4.9 kb and 1.55 kb respectively, which indicated that the carrier was successfully constructed and digested with enzymes. The radioactivity accumulation of QBC(939)HCVC+ and QBC939 cells transfected with mutated IkappaBalpha plasmid was significantly lower than that of the control group not transfected with mutated IkappaBalpha plasmid. Double densimeter scanning showed that the relative signal density between the tansfection group and non-transfection group was significantly different, which proved that the mutated IkappaBalpha plasmid could inhibit the binding activity of NF-kappaB DNA in hilar cholangiocarcinoma cells. Compared to control group not transfected with m IkappaBalpha plasmid, the expression level of MDR-1mRNA in the QBC939 and QBC939HCVC+ cells transfected with mutated IkappaBalpha plasmid was lower. The expression intensity of P-GP protein in QBC939 and QBC939HCVC+ cells transfected with mutated IkappaBalpha was significantly lower than that of the control group not transfected with mutated IkappaBalpha plasmid.
CONCLUSION: The mutated IkappaBalpha plasmid transfection can markedly reverse the multidrug resistance of hilar cholangiocarcinoma cells. Interruption of NF-kappaB activity may become a new target in gene therapy for hilar cholangiocarcinogenesic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655831      PMCID: PMC4250748          DOI: 10.3748/wjg.v11.i5.726

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  11 in total

1.  [Nuclear factor kappa B activity and cell viability of SMMC-7721 inhibited by mutated inhibitor kappa B alpha].

Authors:  Jian-hong Wang; Qing-ke Huang; Min-xin Chen
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2003-04

2.  Induced apoptosis supports spread of adenovirus vectors in tumors.

Authors:  J Mi; Z Y Li; S Ni; D Steinwaerder; A Lieber
Journal:  Hum Gene Ther       Date:  2001-07-01       Impact factor: 5.695

3.  [Expression and clinical significance of mdr-1 gene in lymphoma].

Authors:  Wei-hua Tian; Hai-lin Feng; Jing-song Gao; Wen-qi Jiang
Journal:  Ai Zheng       Date:  2002-08

Review 4.  Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer.

Authors:  Thomas Gilmore; Maria-Emily Gapuzan; Demetrios Kalaitzidis; Daniel Starczynowski
Journal:  Cancer Lett       Date:  2002-07-08       Impact factor: 8.679

5.  Nuclear thyroid hormone receptors in cultured human fibroblasts: improved method of isolation, partial characterization, and interaction with chromatin.

Authors:  K Ichikawa; L J DeGroot; S Refetoff; A L Horwitz; E R Pollak
Journal:  Metabolism       Date:  1986-09       Impact factor: 8.694

6.  Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis.

Authors:  Shuichi Fujioka; Guido M Sclabas; Christian Schmidt; Jiangong Niu; Wayne A Frederick; Qiang G Dong; James L Abbruzzese; Douglas B Evans; Cheryl Baker; Paul J Chiao
Journal:  Oncogene       Date:  2003-03-06       Impact factor: 9.867

7.  Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence.

Authors:  Jeffrey S Ross; Bhaskar V S Kallakury; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Bradley Stringer
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

8.  Specific inhibition of transcription factor NF-kappaB through intracellular protein delivery of I kappaBalpha by the Herpes virus protein VP22.

Authors:  Christopher Stroh; Jürgen Held; Ajoy Kumar Samraj; Klaus Schulze-Osthoff
Journal:  Oncogene       Date:  2003-08-14       Impact factor: 9.867

9.  NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells.

Authors:  Henry Q Xiong; James L Abbruzzese; Edward Lin; Liwei Wang; Leizhen Zheng; Keping Xie
Journal:  Int J Cancer       Date:  2004-01-10       Impact factor: 7.396

10.  Inhibition of NF-kappa B activity by a membrane-transducing mutant of I kappa B alpha.

Authors:  Panagiotis S Kabouridis; Maemunah Hasan; Justine Newson; Derek W Gilroy; Toby Lawrence
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.